METFORMIN-PIOGLITAZONE MARKET

INTRODUCTION

Pioglitazone/metformin, sold under the brand name Actoplus Met among others, is afixed-dose combination anti-diabetic medicationused to improveglycemic controlin adults withtype two diabetes.It containspioglitazone, athiazolidinedione, andmetformin, abiguanide. 

Pioglitazone is a member of the thiazolidinedione class, it decreases insulin resistance in the periphery and in the liver resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output.

Metformin is a member of the biguanide class, improves glucose tolerance in patients with type two diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Pioglitazone/metformin is indicated as an adjunct to diet and exercise:[medical citation needed] To improve glycemic control in patients with type two diabetes, or For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or For patients who have initially responded to pioglitazone alone and require additional glycemic control.

METFORMIN-PIOGLITAZONE MARKET SIZE AND FORECAST

The Global Metformin-Pioglitazone Market accounted for $XX Billion in 20243 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

METFORMIN-PIOGLITAZONE MARKET NEW PRODUCT LAUNCH

Granules Metformin-Pioglitazone METFORMIN+PIOGLITAZONE is a medicine that is used to treat Type 2 diabetes. Type 2 diabetes is a chronic or lifelong condition affecting how your body processes glucose.

People with type 2 diabetes either do not produce enough insulin, or if at all the insulin is produced, it is unable to perform its function in the body (insulin resistance).

Due to this, the blood glucose level increases and symptoms such as frequent urination, increased thirst and increased hunger start. It can lead to serious complications like skin infection, eye problems (retinopathy), nerve damage (neuropathy), diabetic foot (foot ulcer), kidney disease (nephropathy), high blood pressure, and even stroke.

METFORMIN+PIOGLITAZONE contains Gliclazide, metformin and pioglitazone. Gliclazide is a 'sulfonylurea' that acts by increasing the insulin released by the pancreas. On the other hand, Metformin, which is a 'biguanide', acts by lowering the glucose production in the liver, delaying glucose absorption from the intestines and increasing the body's response to insulin.

Pioglitazone works by decreasing the amount of glucose released by the liver and improving the sensitivity of tissues of muscles and fats towards insulin effects.

METFORMIN-PIOGLITAZONE MARKET COMPANY PROFILE

• Gland
• Auro Pharma
• Pfizer
• Emcure pharma
• Granules

THIS METFORMIN-PIOGLITAZONE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Metformin-Pioglitazone  are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Metformin-Pioglitazone  and key vendor selection criteria
3. Where is the Metformin-Pioglitazone  manufactured? What is the average margin per unit?
4. Market share of Global Metformin-Pioglitazone  market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Metformin-Pioglitazone  in-house
6. key predictions for next 5 years in Global Metformin-Pioglitazone  market
7. Average B-2-B Metformin-Pioglitazone  market price in all segments
8. Latest trends in Metformin-Pioglitazone  market, by every market segment
9. The market size (both volume and value) of the Metformin-Pioglitazone  market in 2024-2030 and every year in between?
10. Production breakup of Metformin-Pioglitazone  market, by suppliers and their OEM relationship